Novartis (NVS) has released an update.
Novartis has upgraded its mid-term sales growth guidance, driven by strong market momentum and a robust pipeline of over 30 high-value medicines. The company aims for a core operating income margin of over 40% by 2027, highlighting its focus on innovative medicines and strategic deals to enhance long-term shareholder value. With significant potential in its portfolio, Novartis is poised for sustainable growth, appealing to investors in the financial markets.
For further insights into NVS stock, check out TipRanks’ Stock Analysis page.